Tag: BMY

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:33 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:19 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case
World

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

Updated Nov. 20, 2023 3:16 pm ETBayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller.Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm disorder atrial fibrillation.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8